Tumors Characterized by Genetic Abnormalities of ALK
1 clinical trials · Condition
◉ Watch Tumors Characterized by Genetic Abnormalities of ALK
| Record | Firm | Date |
|---|---|---|
| A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (NCT01283516) | Novartis Pharmaceuticals | 2011-01-24 |
Track Tumors Characterized by Genetic Abnormalities of ALK automatically
Every clearance here is in the API, with alerts when new ones post.